AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

📰

Triple-negative breast carcinoma: the latest breakthroughs

Everything that changed in the last year, from three public sources: phase 3 trials that posted their results, papers in the leading medical and cancer journals, and US drug labels that were updated. Refreshed every week.

🤖

What changed

Written by AI from the evidence below, every point cited

AI reads the results, papers and label updates below and explains what changed and why it matters, citing each source. It is shared with everyone.

🏁

Phase 3 results posted

The large trials that decide new standard treatments · ClinicalTrials.gov
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)NCT03036488 · results posted 2026-10-22 · Merck Sharp & Dohme LLC · 1174 people · tests Pembrolizumab, Carboplatin, Paclitaxel, Doxorubicin MRI and Mammography Before Surgery in Patients With Stage I-II Breast CancerNCT01805076 · results posted 2026-06-26 · Alliance for Clinical Trials in Oncology · 319 people · tests Breast surgery, Magnetic resonance imaging, Mammography A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast CancerNCT04148911 · results posted 2025-12-26 · Hoffmann-La Roche · 184 people · tests Atezolizumab, Nab-Paclitaxel A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast CancerNCT03371017 · results posted 2025-11-12 · Hoffmann-La Roche · 595 people · tests Atezolizumab, Placebo, Gemcitabine, Capecitabine
📚

In the leading journals

NEJM, Lancet, Nature, JCO, Cancer Cell and more · PubMed
ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2.Nature 2026 · PMID 42927884 Clinical Complete Response with Dostarlimab Monotherapy in dMMR/MSI-H Locally Advanced Rectal Cancer: First Results from the Global AZUR-1 …Ann Oncol 2026 · PMID 42927858 From Diagnosis to Destruction: The Rise of Radioligand Therapeutics as Oncology's New Pillar.Ann Oncol 2026 · PMID 42927857 Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label…Ann Oncol 2026 · PMID 42927856 Final prespecified analysis of the phase 3 LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carc…Ann Oncol 2026 · PMID 42927855 Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC expressing PD-L1 ≥50%: The PERSEE rando…Ann Oncol 2026 · PMID 42927854 A randomised phase III trial of adjuvant treatment intensification with mFOLFIRINOX versus mFOLFOX6 in high-risk stage III colon cancer: Re…Ann Oncol 2026 · PMID 42927853 Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer …Lancet Oncol 2026 · PMID 42927765 Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial.Nat Med 2026 · PMID 42926233 Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 tria…Nat Med 2026 · PMID 42926136 Pembrolizumab Plus Chemotherapy for HR+/HER2- PD-L1‒Positive Advanced Breast Cancer: Final Analysis of the Phase 3 KEYNOTE-B49 Study.Ann Oncol 2026 · PMID 42926111 Atirmociclib and fulvestrant for patients with HR+/HER2- advanced/metastatic breast cancer who progressed on a prior cyclin-dependent kinas…Ann Oncol 2026 · PMID 42926110

Want these every week? Follow triple-negative breast carcinoma and get a note on your phone with the new trials and papers.

🔔 Follow triple-negative breast carcinoma
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy